Arcellx/$ACLX

13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX

About Arcellx

Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.

Ticker

$ACLX
Sector
Primary listing

Employees

163

Arcellx Metrics

BasicAdvanced
$4.8B
-
-$3.43
0.28
-

Bulls say / Bears say

The Phase 2 iMMagine-1 trial of anito-cel achieved a 97% overall response rate and 93.3% minimal residual disease negativity in relapsed/refractory multiple myeloma patients as of May 1, 2025, demonstrating potential best-in-class efficacy.
Arcellx finished Q2 2025 with $537.6 million in cash, cash equivalents, and marketable securities, ensuring funding into 2028 and reducing commercialization risk.
The FDA approved an investigational new drug application for ACLX-004, targeting acute myeloid leukemia through Arcellx’s ARC-SparX platform, signifying progress in its pipeline beyond multiple myeloma.
Collaboration revenue fell 72% year-over-year to $7.6 million in Q2 2025, missing analyst forecasts by 43.8%, highlighting the company’s dependence on one-time deal income.
Net loss expanded to $52.8 million in Q2 2025, more than double the $27.2 million loss in Q2 2024, as Arcellx increased spending to prepare for commercial launch planned in 2026.
General and administrative expenses increased 34.1% to $28.7 million in Q2 2025, resulting in higher cash burn as Arcellx ramps up for commercialization without corresponding revenue growth.
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ACLX

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs
Buy Arcellx stock | $ACLX Share Price | Lightyear